Pharmacologic inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK1/2) show clear anti-tumour activity in preventing melanoma cell line growth and survival in vitro[10-14] and in vivo[13,15]. Here, MAP2K1 is linked to melanoma.